Asia Medical and Agricultural Laboratory and Research Center PCL

As of June 30, 2026, Asia Medical and Agricultural Laboratory and Research Center PCL NVDR carries a market capitalization of 1.35B, placing it among publicly traded companies globally. Its enterprise value stands at 1.23B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Asia Medical and Agricultural Laboratory and Research Center PCL NVDR's next confirmed earnings release is scheduled for November 11, 2026.

As of June 30, 2026, Asia Medical and Agricultural Laboratory and Research Center PCL NVDR has 406.33M shares outstanding.

As of June 30, 2026, Asia Medical and Agricultural Laboratory and Research Center PCL NVDR trades at a trailing price-to-earnings ratio of 10.92. The price-to-sales ratio is 3.00, and the price-to-book ratio stands at 2.31.

As of June 30, 2026, Asia Medical and Agricultural Laboratory and Research Center PCL NVDR trades at an EV/EBITDA multiple of 7.33 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 2.66 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 9.79 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. These enterprise value multiples are built on an enterprise value of 1.23B versus a market cap of 1.35B, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, Asia Medical and Agricultural Laboratory and Research Center PCL NVDR maintains a current ratio of 2.49, meaning it holds 2.5x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 4.25, indicating elevated leverage, while an interest coverage ratio of 228.51 demonstrates strong ability to service its debt obligations.

Over the twelve months ended June 30, 2026, Asia Medical and Agricultural Laboratory and Research Center PCL NVDR posted a return on equity (ROE) of 21.21, showing how much profit the company earns on every dollar of shareholder capital. Return on assets (ROA) stands at 17.21, measuring how efficiently the asset base is converted into earnings. The company generates approximately 2.09M in revenue per employee across its workforce of 221.00, a quick read on workforce productivity versus industry peers. Inventory turnover of 17.05 indicates how many times Asia Medical and Agricultural Laboratory and Research Center PCL NVDR sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended June 30, 2026, Asia Medical and Agricultural Laboratory and Research Center PCL NVDR recorded an income tax benefit of -2.17M rather than an expense, typically from losses, carryforwards, or the release of a tax provision. Taxes are levied on pretax income of 124.92M, leaving 127.09M in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

As of the close on October 22, 2026, Asia Medical and Agricultural Laboratory and Research Center PCL NVDR's stock has declined approximately 4.05% over the past 52 weeks. The 50-day moving average sits at 2.98, while the 200-day moving average is 3.19.

Over the twelve months ended June 30, 2026, Asia Medical and Agricultural Laboratory and Research Center PCL NVDR generated 462.46M in revenue and converted that into 127.09M in net income, yielding earnings per share of 0.30. EBITDA reached 167.75M, while operating income came in at 125.65M.

As of June 30, 2026, Asia Medical and Agricultural Laboratory and Research Center PCL NVDR holds 144.18M in cash and equivalents against 24.86M in total debt, resulting in a net debt position of -144.18M. Total book value stands at 584.68M, with working capital of 141.53M providing operational flexibility.

Asia Medical and Agricultural Laboratory and Research Center PCL NVDR produced 144.59M in operating cash flow over the twelve months ended June 30, 2026. After subtracting -46.59M in capital expenditures, free cash flow totaled 98.00M - equivalent to 0.23 per share.

Over the twelve months ended June 30, 2026, Asia Medical and Agricultural Laboratory and Research Center PCL NVDR posted a gross margin of 50.27, reflecting its pricing power and cost economics. The operating margin of 27.17 and net profit margin of 27.48 provide insight into operational efficiency.

Over the twelve months ended June 30, 2026, Asia Medical and Agricultural Laboratory and Research Center PCL NVDR paid dividends of 0.25 per share. The dividend payout ratio of 82.20 indicates the proportion of earnings distributed to shareholders, a key gauge of how sustainable the dividend is and how much room remains for future dividend growth. Free cash flow yield stands at 7.06, showing how much cash the business generates relative to its market value - dividends covered by free cash flow are generally more durable than those funded by debt. Total shareholder yield reaches 12.71, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to Asia Medical and Agricultural Laboratory and Research Center PCL NVDR shareholders.

As of June 30, 2026, Asia Medical and Agricultural Laboratory and Research Center PCL NVDR has an Altman Z-Score of 7.28, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.